secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001104659-25-120146
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer
--------------------------------------------------------------------------------

- Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
- Trial enrolls up to 45 colorectal cancer patients with ctDNA positivity after curative-intent therapy.
- Phase 2a expected to start first half 2026; led by Dr. Paula Pohlmann of MD Anderson Cancer Center.
- Decision based on positive Phase 1 safety data and durable anti-tumor effects.
- TTX-MC138 targets metastatic disease; aims to intervene in minimal residual disease setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925120146/0001104659-25-120146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925120146/tm2533194d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-120146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer